Skip to content

1.         Hirschfield GM, Karlsen TH, Lindor KD, Adams DH. Primary sclerosing cholangitis. The Lancet. 2013;382(9904):1587-99. doi: 10.1016/s0140-6736(13)60096-3.


2.         Karlsen TH, Folseraas T, Thorburn D, Vesterhus M. Primary sclerosing cholangitis - a comprehensive review. J Hepatol. 2017;67(6):1298-323. Epub 2017/08/15. doi: 10.1016/j.jhep.2017.07.022. PubMed PMID: 28802875.


3.         Lunder AK, Hov JR, Borthne A, Gleditsch J, Johannesen G, Tveit K, et al. Prevalence of Sclerosing Cholangitis Detected by Magnetic Resonance Cholangiography in Patients With Long-term Inflammatory Bowel Disease. Gastroenterology. 2016;151(4):660-9 e4. Epub 2016/06/28. doi: 10.1053/j.gastro.2016.06.021. PubMed PMID: 27342213.


4.         European Association for the Study of the L. EASL Clinical Practice Guidelines: Management of cholestatic liver diseases. Journal of Hepatology. 2009;51(2):237-67. doi: 10.1016/j.jhep.2009.04.009.


5.         Chapman RW, Williamson KD. Are Dominant Strictures in Primary Sclerosing Cholangitis a Risk Factor for Cholangiocarcinoma? Current Hepatology Reports. 2017;16(2):124-9. Epub 2017/04/27. doi: 10.1007/s11901-017-0341-2. PubMed PMID: 28706774.


6.         Culver EL, Chapman RW. Systematic review: management options for primary sclerosing cholangitis and its variant forms - IgG4-associated cholangitis and overlap with autoimmune hepatitis. Aliment Pharmacol Ther. 2011;33(12):1273-91. Epub 2011/04/20. doi: 10.1111/j.1365-2036.2011.04658.x. PubMed PMID: 21501198.


7.         Weismuller TJ*, Trivedi PJ*, Bergquist A, Imam M, Lenzen H, Ponsioen CY, et al. Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis. Gastroenterology. 2017;152(8):1975-84 e8. Epub 2017/03/10. doi: 10.1053/j.gastro.2017.02.038. PubMed PMID: 28274849; PubMed Central PMCID: PMCPMC5546611.


8.         Lazaridis KN, LaRusso NF. Primary Sclerosing Cholangitis. N Engl J Med. 2016;375(12):1161-70. Epub 2016/09/23. doi: 10.1056/NEJMra1506330. PubMed PMID: 27653566; PubMed Central PMCID: PMCPMC5553912.


9.         Bowlus CL. Primary sclerosing cholangitis: One disease or several? Clinical Liver Disease. 2014;3(2):34-7. doi: 10.1002/cld.318.


10.       Williamson KD, Chapman RW. Primary sclerosing cholangitis: a clinical update. Br Med Bull. 2015;114(1):53-64. Epub 2015/05/20. doi: 10.1093/bmb/ldv019. PubMed PMID: 25981516.


11.       Liu JZ, Hov JR, Folseraas T, Ellinghaus E, Rushbrook SM, Doncheva NT, et al. Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. Nat Genet. 2013;45(6):670-5. Epub 2013/04/23. doi: 10.1038/ng.2616. PubMed PMID: 23603763; PubMed Central PMCID: PMCPMC3667736.


12.       Fosby B, Karlsen TH, Melum E. Recurrence and rejection in liver transplantation for primary sclerosing cholangitis. World J Gastroenterol. 2012;18(1):1-15. doi: 10.3748/wjg.v18.i1.1. PubMed PMID: 22228965.


13.       Liaskou E, Hirschfield GM. Genetic Distinctions in Patients With Primary Sclerosing Cholangitis: Immunoglobulin G4 Elevations and HLA Risk. Gastroenterology. 2015;148(5):886-9. Epub 2015/03/26. doi: 10.1053/j.gastro.2015.03.021. PubMed PMID: 25805418.


14.       Chung BK, Hirschfield GM. Immunogenetics in primary sclerosing cholangitis. Curr Opin Gastroenterol. 2017;33(2):93-8. Epub 2017/02/02. doi: 10.1097/MOG.0000000000000336. PubMed PMID: 28146446.


15.       Ji SG, Juran BD, Mucha S, Folseraas T, Jostins L, Melum E, et al. Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease. Nat Genet. 2017;49(2):269-73. Epub 2016/12/20. doi: 10.1038/ng.3745. PubMed PMID: 27992413; PubMed Central PMCID: PMCPMC5540332.


16.       Jiang X, Karlsen TH. Genetics of primary sclerosing cholangitis and pathophysiological implications. Nature Reviews Gastroenterology & Hepatology. 2017;14:279. doi: 10.1038/nrgastro.2016.154


17.       Trivedi PJ, Hirschfield GM. The Immunogenetics of Autoimmune Cholestasis. Clin Liver Dis. 2016;20(1):15-31. Epub 2015/11/26. doi: 10.1016/j.cld.2015.08.002. PubMed PMID: 26593288; PubMed Central PMCID: PMCPMC4681448.


18.       Tilg H, Grander C, Moschen AR. How does the microbiome affect liver disease? Clinical Liver Disease. 2016;8(5):123-6. doi: 10.1002/cld.586.


19.       Sabino J, Vieira-Silva S, Machiels K, Joossens M, Falony G, Ballet V, et al. Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD. Gut. 2016;65(10):1681-9. Epub 2016/05/22. doi: 10.1136/gutjnl-2015-311004. PubMed PMID: 27207975; PubMed Central PMCID: PMCPMC5036217.


20.       Karlsen TH. Primary sclerosing cholangitis: 50 years of a gut–liver relationship and still no love? Gut. 2016;65(10):1579. doi: 10.1136/gutjnl-2016-312137.


21.       Quraishi MN, Sergeant M, Kay G, Iqbal T, Chan J, Constantinidou C, et al. The gut-adherent microbiota of PSC-IBD is distinct to that of IBD. Gut. 2017;66(2):386-8. Epub 2016/05/20. doi: 10.1136/gutjnl-2016-311915. PubMed PMID: 27196590.


22.       Chapman RW. Primary sclerosing cholangitis. Medicine. 2015;43(11):648-52. doi: 10.1016/j.mpmed.2015.08.003.


23.       Webb G RR, Marshall T, Hirschfield GM. Posters (Abstract 330 Autoimmune liver disease in the UK: a national primary care evaluation of disease geoepidemiology).  The Liver Meeting; 2017/10/01. Hepatology: John Wiley & Sons, Ltd; 2017. p. 149-1185.


24.       Liang H, Manne S, Shick J, Lissoos T, Dolin P. Incidence, prevalence, and natural history of primary sclerosing cholangitis in the United Kingdom. Medicine. 2017;96(24). doi: 10.1097/MD.0000000000007116.


25.       Lindkvist B, Benito de Valle M, Gullberg B, Björnsson E. Incidence and prevalence of primary sclerosing cholangitis in a defined adult population in Sweden. Hepatology. 2010;52(2):571-7. doi: 10.1002/hep.23678.


26.       Andersen IM, Tengesdal G, Lie BA, Boberg KM, Karlsen TH, Hov JR. Effects of coffee consumption, smoking, and hormones on risk for primary sclerosing cholangitis. Clin Gastroenterol Hepatol. 2014;12(6):1019-28. Epub 2013/10/01. doi: 10.1016/j.cgh.2013.09.024. PubMed PMID: 24076415.


27.       Hackshaw A, Morris JK, Boniface S, Tang J-L, Milenković D. Low cigarette consumption and risk of coronary heart disease and stroke: meta-analysis of 141 cohort studies in 55 study reports. BMJ. 2018;360:j5855. doi: 10.1136/bmj.j5855.


28.       Johnson KC. Just one cigarette a day seriously elevates cardiovascular risk. BMJ. 2018;360:k167. doi: 10.1136/bmj.k167.


29.       How smoking affects your body NHS2018 [cited 2018 25 January 2018]. Available from:


30.       Lammert C, Juran BD, Schlicht E, Xie X, Atkinson EJ, de Andrade M, et al. Reduced Coffee Consumption Among Individuals With Primary Sclerosing Cholangitis but Not Primary Biliary Cirrhosis. Clinical Gastroenterology and Hepatology. 2014;12(9):1562-8. doi: 10.1016/j.cgh.2013.12.036.


31.       Friedrich K, Smit M, Wannhoff A, Rupp C, Scholl SG, Antoni C, et al. Coffee consumption protects against progression in liver cirrhosis and increases long-term survival after liver transplantation. Journal of Gastroenterology and Hepatology. 2016;31(8):1470-5. doi: 10.1111/jgh.13319.


32.       Molodecky NA, Kareemi H, Parab R, Barkema HW, Quan H, Myers RP, et al. Incidence of primary sclerosing cholangitis: a systematic review and meta-analysis. Hepatology. 2011;53(5):1590-9. Epub 2011/02/26. doi: 10.1002/hep.24247. PubMed PMID: 21351115.


33.       McNally RJQ, James PW, Ducker S, Norman PD, James OFW. No rise in incidence but geographical heterogeneity in the occurrence of primary biliary cirrhosis in North East England. American Journal of Epidemiology. 2014;179(4):492-8. Epub 2014/01/08. doi: 10.1093/aje/kwt308. PubMed PMID: 24401563.


34.       Bergquist A, Lindberg G, Saarinen S, Broome U. Increased prevalence of primary sclerosing cholangitis among first-degree relatives. J Hepatol. 2005;42(2):252-6. Epub 2005/01/25. doi: 10.1016/j.jhep.2004.10.011. PubMed PMID: 15664252.


35.       Walmsley M. Clinical need in PSC and clinically meaningful change: What is important to patients? PSC Support2016 [cited 2019 01 January 2019]. Available from:


36.       Kim WR, Therneau TM, Wiesner RH, Poterucha JJ, Benson JT, Malinchoc M, et al. A Revised Natural History Model for Primary Sclerosing Cholangitis. Mayo Clinic Proceedings. 2000;75(7):688-94. doi: 10.4065/75.7.688.


37.       Goode EC, Clark AB, Mells GM, Srivastava B, Spiess K, Gelson WTH, et al. Factors Associated With Outcomes of Patients With Primary Sclerosing Cholangitis and Development and Validation of a Risk Scoring System. Hepatology. 2018;0(ja). doi: 10.1002/hep.30479.


38.       Eaton JE, Vesterhus M, McCauley BM, Atkinson EJ, Schlicht EM, Juran BD, et al. Primary Sclerosing Cholangitis Risk Estimate Tool (PREsTo) Predicts Outcomes of the Disease: A Derivation and Validation Study Using Machine Learning. Hepatology. 2018;0(0). doi: 10.1002/hep.30085.


39.       de Vries EM, Wang J, Williamson KD, Leeflang MM, Boonstra K, Weersma RK, et al. A novel prognostic model for transplant-free survival in primary sclerosing cholangitis. Gut. 2018;67(10):1864. doi: 10.1136/gutjnl-2016-313681.


40.       Al Mamari S, Djordjevic J, Halliday JS, Chapman RW. Improvement of serum alkaline phosphatase to <1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis. Journal of Hepatology. 2013;58(2):329-34. doi: 10.1016/j.jhep.2012.10.013.


41.       Nielsen MJ, Thorburn D, Leeming DJ, Hov JR, Nygård S, Moum B, et al. Serological markers of extracellular matrix remodeling predict transplant-free survival in primary sclerosing cholangitis. Alimentary Pharmacology & Therapeutics. 2018;48(2):179-89. doi: 10.1111/apt.14806.


42.       Vesterhus M, Hov JR, Holm A, Schrumpf E, Nygård S, Godang K, et al. Enhanced liver fibrosis score predicts transplant-free survival in primary sclerosing cholangitis. Hepatology. 2015;62(1):188-97. doi: 10.1002/hep.27825.


43.       de Vries EMG, Färkkilä M, Milkiewicz P, Hov JR, Eksteen B, Thorburn D, et al. Enhanced liver fibrosis test predicts transplant-free survival in primary sclerosing cholangitis, a multi-centre study. Liver International. 2017;37(10):1554-61. doi: 10.1111/liv.13402.


44.       Ponsioen CY, Lindor KD, Mehta R, Dimick-Santos L. Design and Endpoints for Clinical Trials in Primary Sclerosing Cholangitis. Hepatology. 2018;68(3):1174-88. doi: 10.1002/hep.29882.


45.       Ponsioen CY, Chapman RW, Chazouillères O, Hirschfield GM, Karlsen TH, Lohse AW, et al. Surrogate endpoints for clinical trials in primary sclerosing cholangitis: Review and results from an International PSC Study Group consensus process. Hepatology. 2016;63(4):1357-67. doi: 10.1002/hep.28256.


46.       Lamberts LE, Janse M, Haagsma EB, van den Berg AP, Weersma RK. Immune-mediated diseases in primary sclerosing cholangitis. Digestive and Liver Disease. 2011;43(10):802-6. doi: 10.1016/j.dld.2011.05.009.


47.       Gregorio GV, Portmann B, Karani J, Harrison P, Donaldson PT, Vergani D, et al. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: A 16-year prospective study. Hepatology. 2001;33(3):544-53. doi: 10.1053/jhep.2001.22131.


48.       Dyson JK, Beuers U, Jones DEJ, Lohse AW, Hudson M. Primary sclerosing cholangitis. The Lancet. 2018;391(10139):2547-59.doi: 10.1016/S0140-6736(18)30300-3.


49.       Haldar D, Hirschfield GM. Overlap syndrome: A real syndrome? Clinical Liver Disease. 2014;3(3):43-7. doi: 10.1002/cld.317.


50.       Hirschfield GM, Gershwin ME. The Immunobiology and Pathophysiology of Primary Biliary Cirrhosis. Annual Review of Pathology: Mechanisms of Disease. 2013;8(1):303-30. doi: 10.1146/annurev-pathol-020712-164014.


51.       Floreani A, Franceschet I, Cazzagon N, Spinazzè A, Buja A, Furlan P, et al. Extrahepatic Autoimmune Conditions Associated with Primary Biliary Cirrhosis. Clinical Reviews in Allergy & Immunology. 2015;48(2):192-7. doi: 10.1007/s12016-014-8427-x.


52.       Newsome PN, Cramb R, Davison SM, Dillon JF, Foulerton M, Godfrey EM, et al. Guidelines on the management of abnormal liver blood tests. Gut. 2018;67(1):6. doi: 10.1136/gutjnl-2017-314924.


53.       Gwela A, Arancibia-Cárcamo CV, Siddhanathi P, Chapman RW, Travis S, Geremia A, et al. Th1 and Innate Lymphoid Cells Accumulate in Primary Sclerosing Cholangitis-associated Inflammatory Bowel Disease. Journal of Crohn's and Colitis. 2017;11(9):1124-34. doi: 10.1093/ecco-jcc/jjx050.


54.       Fredricsson A, Rorsman F, Vessby J, Carlson M, Lampinen M, Wanders A. High Serum sCD40 and a Distinct Colonic T Cell Profile in Ulcerative Colitis Associated With Primary Sclerosing Cholangitis. Journal of Crohn's and Colitis. 2018. doi: 10.1093/ecco-jcc/jjy170.


55.       Halliday JS, Djordjevic J, Lust M, Culver EL, Braden B, Travis SP, et al. A unique clinical phenotype of primary sclerosing cholangitis associated with Crohn's disease. Journal of Crohn's and Colitis. 2012;6(2):174-81. Epub 2012/02/14. doi: 10.1016/j.crohns.2011.07.015. PubMed PMID: 22325171.


56.       Cleland J, Pavlides M, Rahman M, Chapman R, Travis S, Christian A, et al. Outcomes after ileal pouch anal anastomosis in patients with primary sclerosing cholangitis. Journal of Crohn's and Colitis. 2014;8(7):662-70. doi: 10.1016/j.crohns.2013.12.007.


57.       Jess T, Simonsen J, Jørgensen KT, Pedersen BV, Nielsen NM, Frisch M. Decreasing Risk of Colorectal Cancer in Patients With Inflammatory Bowel Disease Over 30 Years. Gastroenterology. 2012;143(2):375-81.e1. doi: 10.1053/j.gastro.2012.04.016.


58.      Chapman MH, Thorburn D, Hirschfield GM, et al. British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis. Gut. Published Online First: 01 June 2019. doi:10.1136/ gutjnl-2018-317993


59.       Culver EL, Barnes E. IgG4-related sclerosing cholangitis. Clinical Liver Disease. 2017;10(1):9-16. doi: 10.1002/cld.642.


60.       Smit WL, Culver EL, Chapman RW. New Thoughts on Immunoglobulin G4–Related Sclerosing Cholangitis. Clinics in Liver Disease. 2016;20(1):47-65. doi: 10.1016/j.cld.2015.08.004.


61.       Webster GJM, Pereira SP, Chapman RW. Autoimmune pancreatitis/IgG4-associated cholangitis and primary sclerosing cholangitis – Overlapping or separate diseases? Journal of Hepatology. 2009;51(2):398-402. doi: 10.1016/j.jhep.2009.04.010.


62.       Berntsen NL, Klingenberg O, Juran BD, Benito de Valle M, Lindkvist B, Lazaridis KN, et al. Association Between HLA Haplotypes and Increased Serum Levels of IgG4 in Patients With Primary Sclerosing Cholangitis. Gastroenterology. 2015;148(5):924-7.e2. doi: 10.1053/j.gastro.2015.01.041.


63.       Boonstra K, Culver EL, de Buy Wenniger LM, van Heerde MJ, van Erpecum KJ, Poen AC, et al. Serum immunoglobulin G4 and immunoglobulin G1 for distinguishing immunoglobulin G4-associated cholangitis from primary sclerosing cholangitis. Hepatology. 2014;59(5):1954-63. doi: 10.1002/hep.26977.


64.       Mendes FD, Jorgensen R, Keach J, Katzmann JA, Smyrk T, Donlinger J, et al. Elevated Serum IgG4 Concentration in Patients with Primary Sclerosing Cholangitis. The American Journal Of Gastroenterology. 2006;101:2070. doi: 10.1111/j.1572-0241.2006.00772.x.


65.       Braden B, Halliday J, Aryasingha S, Sharifi Y, Checchin D, Warren BF, et al. Risk for Colorectal Neoplasia in Patients With Colonic Crohn's Disease and Concomitant Primary Sclerosing Cholangitis. Clinical Gastroenterology and Hepatology. 2012;10(3):303-8. doi: 10.1016/j.cgh.2011.10.020.


66.       Razumilava N, Gores GJ. Surveillance for cholangiocarcinoma in patients with primary sclerosing cholangitis: Effective and justified? Clinical Liver Disease. 2016;8(2):43-7. doi: 10.1002/cld.567.


67.       Aabakken L, Karlsen TH, Albert J, Arvanitakis M, Chazouilleres O, Dumonceau J-M, et al. Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline. Journal of Hepatology. 2017;66(6):1265-81. doi: 10.1016/j.jhep.2017.02.013.


68.       Chapman R, Fevery J, Kalloo A, Nagorney DM, Boberg KM, Shneider B, et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology. 2010;51(2):660-78. doi: 10.1002/hep.23294.


69.       Khaderi SA, Sussman NL. Screening for Malignancy in Primary Sclerosing Cholangitis (PSC). Current Gastroenterology Reports. 2015;17(4):17. doi: 10.1007/s11894-015-0438-0.


70.       Overview: Osteoporosis NHS2016 [cited 2018 01 February 2018]. Available from:


71.       Angulo P, Grandison GA, Fong DG, Keach JC, Lindor KD, Bjornsson E, et al. Bone Disease in Patients With Primary Sclerosing Cholangitis. Gastroenterology. 2011;140(1):180-8. doi: 10.1053/j.gastro.2010.10.014.


72.       Collier JD, Ninkovic M, Compston JE. Guidelines on the management of osteoporosis associated with chronic liver disease. Gut. 2002;50(suppl 1):i1. doi: 10.1136/gut.50.suppl_1.i1.


73.       Trivedi PJ, Corpechot C, Pares A, Hirschfield GM. Risk stratification in autoimmune cholestatic liver diseases: Opportunities for clinicians and trialists. Hepatology. 2016;63(2):644-59. Epub 2015/08/21. doi: 10.1002/hep.28128. PubMed PMID: 26290473; PubMed Central PMCID: PMCPMC4864755.


74.       Boonstra K, Weersma RK, van Erpecum KJ, Rauws EA, Spanier BW, Poen AC, et al. Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology. 2013;58(6):2045-55. Epub 2013/06/19. doi: 10.1002/hep.26565. PubMed PMID: 23775876.


75.       Trivedi PJ, Hirschfield GM. Treatment of autoimmune liver disease: current and future therapeutic options. Therapeutic Advances in Chronic Disease. 2013;4(3):119-41. doi: 10.1177/2040622313478646. PubMed PMID: 23634279.


76.       Corpechot C, Gaouar F, Chrétien Y, Johanet C, Chazouillères O, Poupon R. Smoking as an independent risk factor of liver fibrosis in primary biliary cirrhosis. Journal of Hepatology. 2012;56(1):218-24. doi: 10.1016/j.jhep.2011.03.031.


77.       Juran BD, Lazaridis KN. Environmental factors in primary biliary cirrhosis. Seminars in Liver Disease. 2014;34(3):265-72. Epub 2014/07/24. doi: 10.1055/s-0034-1383726. PubMed PMID: 25057950.


78.       Goode EC, Rushbrook SM. A review of the medical treatment of primary sclerosing cholangitis in the 21st century. Therapeutic Advances in Chronic Disease. 2016;7(1):68-85. doi: 10.1177/2040622315605821. PubMed PMID: 26770670.


79.       Staufer K, Kivaranovic D, Rasoul-Rockenschaub S, Soliman T, Trauner M, Berlakovich G. Waitlist mortality and post-transplant survival in patients with cholestatic liver disease – Impact of changes in allocation policy. HPB. 2018;20(10):916-24. doi: 10.1016/j.hpb.2018.03.013.


80.       Liver Transplantation: Selection Criteria and Recipient Registration. NHS Blood and Transplant ODT website. 2018 [updated April 2018; cited 2018 28 June]. Available from:


81.       Donation after brainstem death. NHS Blood and Transplant ODT website. [cited 2018 09 July]. Available from:


82.       Donation after circulatory death. NHS Blood and Transplant ODT website. [cited 2018 9 July]. Available from:


83.       Trivedi PJ, Scalera I, Slaney E, Laing RW, Gunson B, Hirschfield GM, et al. Clinical outcomes of donation after circulatory death liver transplantation in primary sclerosing cholangitis. J Hepatol. 2017;67(5):957-65. Epub 2017/07/12. doi: 10.1016/j.jhep.2017.06.027. PubMed PMID: 28690174.


84.       Goldman KE. Dental management of patients with bone marrow and solid organ transplantation. Dent Clin North Am. 2006;50(4):659-76, viii. Epub 2006/09/27. doi: 10.1016/j.cden.2006.06.009. PubMed PMID: 17000279.


85.       Guggenheimer J, Eghtesad B, Stock DJ. Dental management of the (solid) organ transplant patient. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003;95(4):383-9. Epub 2003/04/11. doi: 10.1067/moe.2003.150. PubMed PMID: 12686921.


86.       Firriolo FJ. Dental management of patients with end-stage liver disease. Dent Clin North Am. 2006;50(4):563-90, vii. Epub 2006/09/27. doi: 10.1016/j.cden.2006.06.007. PubMed PMID: 17000274.


87.       Trivedi PJ, Reece J, Laing RW, Slaney E, Cooney R, Gunson BK, et al. The impact of ileal pouch-anal anastomosis on graft survival following liver transplantation for primary sclerosing cholangitis. Aliment Pharmacol Ther. 2018;48(3):322-32. Epub 2018/06/09. doi: 10.1111/apt.14828. PubMed PMID: 29882252.


88.       Live Donor Information for Potential Living Liver Donors. NHS Leeds Teaching Hospital website. 2016 [cited 2018 9 July]. Available from:


89.       Organ Donation and Transplantation Activity Report 2017/18. NHS Blood and Transplant ODT website. 2018 [cited 2018 9 July]. Available from:


90.       Williams R. Liver disease in the UK: Startling findings & urgent need for action. Journal of Hepatology. 2015;63(2):297-9. doi: 10.1016/j.jhep.2015.04.022.


91.       Organ Donation and Transplantation Statistics about Organ Donation. NHS Blood and Transplant ODT website. 2018 [cited 2018 09 July]. Available from:


92.       Deceased Donor Liver Distribution and Allocation. NHS Blood and Transplant ODT website. 2018 [updated April 2018; cited 2018 28 June]. Available from:


93.       Annual Report on Liver Transplantation 2015/16 NHS Blood and Transplant ODT website2016 [cited 2017 13 July]. Available from:


94.       Lindor KD, Kowdley KV, Luketic VAC, Harrison ME, McCashland T, Befeler AS, et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology. 2009;50(3):808-14. doi: 10.1002/hep.23082.


95.       Volk ML. Risks of Using Ursodeoxycholic Acid to Treat Primary Sclerosing Cholangitis. Gastroenterology. 2011;141(6):2267-8. doi: 10.1053/j.gastro.2011.10.003.


96.       Poropat G, Giljaca V, Stimac D, Gluud C. Bile acids for primary sclerosing cholangitis. Cochrane Database Syst Rev [Internet]. 2011 2011/01//; (1):[CD003626 p.]. Available from:


97.       Lindström L, Hultcrantz R, Boberg KM, Friis–Liby I, Bergquist A. Association Between Reduced Levels of Alkaline Phosphatase and Survival Times of Patients With Primary Sclerosing Cholangitis. Clinical Gastroenterology and Hepatology. 2013;11(7):841-6. doi: 10.1016/j.cgh.2012.12.032.


98.       Claessen MMH, Vleggaar FP, Tytgat KMAJ, Siersema PD, van Buuren HR. High lifetime risk of cancer in primary sclerosing cholangitis. Journal of Hepatology. 2009;50(1):158-64. doi: 10.1016/j.jhep.2008.08.013.


99.       Pardi DS, Loftus EV, Jr., Kremers WK, Keach J, Lindor KD. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology. 2003;124(4):889-93. doi: 10.1053/gast.2003.50156.


100.     Eaton JE, Silveira MG, Pardi DS, Sinakos E, Kowdley KV, Luketic VAC, et al. High-Dose Ursodeoxycholic Acid Is Associated With the Development of Colorectal Neoplasia in Patients With Ulcerative Colitis and Primary Sclerosing Cholangitis. The American Journal Of Gastroenterology. 2011;106:1638. doi: 10.1038/ajg.2011.156.


101.     Vítek L, Zelenková M, Brůha R. Safe use of ursodeoxycholic acid in a breast-feeding patient with primary biliary cirrhosis. Digestive and Liver Disease. 2010;42(12):911-2. doi: 10.1016/j.dld.2010.06.002.


102.     Lindor KD, Kowdley KV, Harrison ME. ACG Clinical Guideline: Primary Sclerosing Cholangitis. The American Journal Of Gastroenterology. 2015;110:646. doi: 10.1038/ajg.2015.112.


103.     Chapman RW. High-dose ursodeoxycholic acid in the treatment of primary sclerosing cholangitis: Throwing the urso out with the bathwater? Hepatology. 2009;50(3):671-3. doi: 10.1002/hep.23174.


104.     Wunsch E, Trottier J, Milkiewicz M, Raszeja-Wyszomirska J, Hirschfield GM, Barbier O, et al. Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis. Hepatology. 2014;60(3):931-40. doi: 10.1002/hep.27074.


105.     Tabibian JH, Lindor KD. Ursodeoxycholic acid in primary sclerosing cholangitis: If withdrawal is bad, then administration is good (right?). Hepatology. 2014;60(3):785-8. doi: 10.1002/hep.27180.


106.     European Association for Study of L, Asociacion Latinoamericana para el Estudio del H. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63(1):237-64. Epub 2015/04/26. doi: 10.1016/j.jhep.2015.04.006. PubMed PMID: 25911335.


107.     Cairns SR, Scholefield JH, Steele RJ, Dunlop MG, Thomas HJW, Evans GD, et al. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut. 2010;59(5):666. doi: 10.1136/gut.2009.179804.


108.     Sagvand BT, Edwards K, Shen B. 560 - Gallbladder Polyps in Patients with Primary Sclerosing Cholangitis; Frequency, Risk Factors and Outcome. Gastroenterology. 2018;154(6):S-1097-S-8. doi: 10.1016/S0016-5085(18)33654-0.


109.     Zenouzi R, Weismüller TJ, Hübener P, Schulze K, Bubenheim M, Pannicke N, et al. Low Risk of Hepatocellular Carcinoma in Patients With Primary Sclerosing Cholangitis With Cirrhosis. Clinical Gastroenterology and Hepatology. 2014;12(10):1733-8. doi: 10.1016/j.cgh.2014.02.008.


110.     Bergquist A, Ekbom A, Olsson R, Kornfeldt D, Lööf L, Danielsson Å, et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. Journal of Hepatology. 2002;36(3):321-7. doi: 10.1016/S0168-8278(01)00288-4.


111.     Boberg KM, Lind GE. Primary sclerosing cholangitis and malignancy. Best Practice & Research Clinical Gastroenterology. 2011;25(6):753-64. doi:


112.     Silva M, Gomes S, Peixoto A, Torres-Ramalho P, Cardoso H, Azevedo R, et al. Nutrition in Chronic Liver Disease. GE Portuguese Journal of Gastroenterology. 2015;22(6):268-76. doi: 10.1016/j.jpge.2015.06.004. PubMed PMID: 28868418.


113.     Jorgensen RA, Lindor KD, Sartin JS, LaRusso NF, Wiesner RH. Serum lipid and fat-soluble vitamin levels in primary sclerosing cholangitis. J Clin Gastroenterol. 1995;20(3):215-9. PubMed PMID: 7797830.


114.     Johnson J. PSC: Eating for Health [VIDEO]. PSC Support Online2016 [cited 2016 24 November]. Available from:


115.     Simren M, Olsson R, Chapman RW. Fatigue in patients with primary sclerosing cholangitis AU - Björnsson, E. Scandinavian Journal of Gastroenterology. 2004;39(10):961-8. doi: 10.1080/00365520410003434.


116.     Dyson JK, Elsharkawy AM, Lamb CA, Al-Rifai A, Newton JL, Jones DE, et al. Fatigue in primary sclerosing cholangitis is associated with sympathetic over-activity and increased cardiac output. Liver International. 2015;35(5):1633-41. doi: 10.1111/liv.12709.


117.     de Valle MB, Rahman M, Lindkvist B, Bjornsson E, Chapman RW, Kalaitzakis E. M1046 Fatigue in Patients With Primary Sclerosing Cholangitis: An International Survey Study in Two Population-Based Patient Cohorts. Gastroenterology. 2010;138(5):S-320.doi: 10.1016/S0016-5085(10)61472-2.


118.     de Jong DJ, Nagengast FM, van Vugt-van Pinxteren MWJ, Römkens TEH, van Oijen MGH. High prevalence of fatigue in inflammatory bowel disease: A case control study. Journal of Crohn's and Colitis. 2011;5(4):332-7. doi: 10.1016/j.crohns.2011.02.008.


119.     Fulcher KY, White PD. Randomised controlled trial of graded exercise in patients with the chronic fatigue syndrome. BMJ. 1997;314(7095):1647. doi: 10.1136/bmj.314.7095.1647.


120.     Jones EA, Bergasa NV. The pruritus of cholestasis. Hepatology. 1999;29(4):1003-6. doi: 10.1002/hep.510290450.


121.     Zakharia K, Tabibian A, Lindor KD, Tabibian JH. Complications, symptoms, quality of life and pregnancy in cholestatic liver disease. Liver Int. 2018;38(3):399-411. Epub 2017/09/19. doi: 10.1111/liv.13591. PubMed PMID: 28921801.


122.     Webb GJ, Rahman SR, Levy C, Hirschfield GM. Low risk of hepatotoxicity from rifampicin when used for cholestatic pruritus: a cross-disease cohort study. Alimentary Pharmacology & Therapeutics. 2018;47(8):1213-9. doi: 10.1111/apt.14579.


123.     Benito de Valle M, Rahman M, Lindkvist B, Björnsson E, Chapman R, Kalaitzakis E. Factors That Reduce Health-Related Quality of Life in Patients With Primary Sclerosing Cholangitis. Clinical Gastroenterology and Hepatology. 2012;10(7):769-75.e2. doi: 10.1016/j.cgh.2012.01.025.


124.     Broomé U, Olsson R, Lööf L, Bodemar G, Hultcrantz R, Danielsson A, et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut. 1996;38(4):610. doi: 10.1136/gut.38.4.610.


125.     Hirschfield GM. What pain relief can people with PSC take? In: Walmlsey M, editor. PSC Support. 2018.


126.     Aldridge DR, Tranah EJ, Shawcross DL. Pathogenesis of Hepatic Encephalopathy: Role of Ammonia and Systemic Inflammation. Journal of Clinical and Experimental Hepatology. 2015;5:S7-S20. doi: 10.1016/j.jceh.2014.06.004.


127.     Shawcross DL, Jalan R. Treatment of hepatic encephalopathy: it's not lactulose. BMJ (Clinical research ed). 2004;329(7457):112-. doi: 10.1136/bmj.329.7457.112. PubMed PMID: 15242927.


128.     Salehi S, Lim S, Heneghan M, Aluvihare V, Heaton N, Patel V, et al. Rifaximin reduces the incidence of sepsis and all cause admissions whilst on the liver transplant waiting list. Journal of Hepatology. 2018;68:S119-S20. doi: 10.1016/S0168-8278(18)30454-9.


129.     Schramm C, Eaton J, Ringe KI, Venkatesh S, Yamamura J, IPSCSG MRIwgot. Recommendations on the use of magnetic resonance imaging in PSC-A position statement from the International PSC Study Group. Hepatology. 2017;66(5):1675-88. Epub 2017/05/31.doi: 10.1002/hep.29293. PubMed PMID: 28555945.


130.     Cotter JM, Mack CL. Primary sclerosing cholangitis: Unique aspects of disease in children. Clinical Liver Disease. 2017;10(5):120-3. doi: 10.1002/cld.672.


131.     Barnabas A, Chapman RW. Primary Sclerosing Cholangitis: Is Any Treatment Worthwhile? Current Gastroenterology Reports. 2012;14(1):17-24. doi: 10.1007/s11894-011-0230-8.


132.     Ponsioen CY, Arnelo U, Bergquist A, Rauws EA, Paulsen V, Cantú P, et al. No Superiority of Stents vs Balloon Dilatation for Dominant Strictures in Patients With Primary Sclerosing Cholangitis. Gastroenterology. 2018;155(3):752-9.e5. doi: 10.1053/j.gastro.2018.05.034.


133.     Jackson J. Healthy Eating British Dietetic Association2016 [cited 2019 11 January]. Available from:


134.     Wiencke K, Boberg KM. Current consensus on the management of primary sclerosing cholangitis. Clinics and Research in Hepatology and Gastroenterology. 2011;35(12):786-91. doi:


135.     Vestergaard EM, Hein HO, Meyer H, Grunnet N, Jørgensen J, Wolf H, et al. Reference Values and Biological Variation for Tumor Marker CA 19-9 in Serum for Different Lewis and Secretor Genotypes and Evaluation of Secretor and Lewis Genotyping in a Caucasian Population. Clinical Chemistry. 1999;45(1):54.

136.     Slade A, Isa F, Kyte D, Pankhurst T, Kerecuk L, Ferguson J, Lipkin G, Calvert M. Patient reported outcome measures in rare diseases: a narrative review. Orphanet journal of rare diseases. 2018 Dec;13(1):61.


137.     Isa F, Turner GM, Kaur G, Kyte D, Slade A, Pankhurst T, Kerecuk L, Keeley T, Ferguson J, Calvert M. Patient-reported outcome measures used in patients with primary sclerosing cholangitis: a systematic review. Health and quality of life outcomes. 2018 Dec;16(1):133.


138.     Low JT, Davis S, Greenslade L, Carroll C, Craig R, Wilson J, Clancy JL, Marshall A, Thorburn D, Stone P. Improving Communication in Outpatient Consultations in People With Cirrhosis: The Development of a Question Prompt List (QPL). Journal of Clinical Gastroenterology. 2020 Apr 14. doi: 10.1097/MCG.0000000000001347


139.       Organ Donation and Transplantation Activity Report 2019/20. NHS Blood and Transplant ODT website. 2020 [cited 2020 18 July]. Available from:


140.       Walmsley M, Leburgue A, Thorburn D, Hirschfield G, Trivedi P. Identifying research priorities in primary sclerosing cholangitis: driving clinically meaningful change from the patients’ perspective. J Hepatol. 2019 Apr 1;70:e412-3.


141. Annual Report on Liver Transplantation 2020/21. NHS Blood and Transplant ODT website. 2021 [cited 2021 25 Sep]. Available from:

142. Organ Donation and Transplantation Activity Report 2020/21. NHS Blood and Transplant ODT website. 2021 [cited 2021 25 Sep]. Available from: